USO 23284
Un estudio de fase 3, multicéntrico, aleatorizado y abierto de Etentamig comparado con las terapias estándar disponibles en sujetos con mieloma múltiple en recaída o refractario (estudio de monoterapia 3L+ RRMM) (M22-574)
Tipos de enfermedades: Linfoma y Hematología
Requisitos de elegibilidad:
Eastern Cooperative Oncology Group (ECOG) performance of <= 2.
Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol.
Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment:
In participants without measurable serum or urine M protein, serum free light chain (FLC) >= 100 mg/L (10 mg/dL) (involved light chain)and an abnormal serum kappa lambda ratio.
Must have received at least 2 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody (mAb).
Must be eligible to receive the Investigator's choice standard available therapy (SAT) based on approved prescribing information, previous MM treatment history, and institutional guidelines.
Para más información sobre este juicio , HAGA CLIC AQUÍ.
Disponible en: